INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript March 30, 2026 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.26. Operator: Greetings, and ...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage ...

As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop ...

Released top-line data from the MINDFuL phase 2 trial in 208 patients with MCI and early Alzheimer’s. The trial missed its primary cognitive endpoints in the 200 modified mITT patients enrolled, ...

The company’s reliance on future clinical trial results introduces significant uncertainty regarding the potential success of its drug candidates, highlighting risks that may deter investors. The ...

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. A transcript ...

INmune Bio Inc (INMB) reports significant progress in clinical trials and regulatory plans, despite increased net loss and asset impairment.

A downtrend has been apparent in INmune Bio, Inc. (INMB) lately. While the stock has lost 11.9% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its ...

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 ...

Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...

Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the second half of June. Presented baseline demographics and disease profiles of participants in the MINDFuL phase II study ...